Many studies have shown that different ALK inhibitors, including crizotinib (Xalkori), ceritinib (Zykadia), brigatinib (Alunbrig), and alectinib (Alecensa), possess higher therapeutic efficacy than platinum-based chemotherapy against metastatic NSCLC positive to EML4-ALK fusions [72,73,74,75]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.